FS Reports最新文献

{"title":"Unlocking new horizons in egg donation: clinical and logistical benefits of double ovarian stimulation","authors":"María Cruz Ph.D.,&nbsp;Elizabet Henzenn M.D.,&nbsp;Antonio Requena Ph.D., M.D.","doi":"10.1016/j.xfre.2025.12.001","DOIUrl":"10.1016/j.xfre.2025.12.001","url":null,"abstract":"<div><h3>Objective</h3><div>To study the clinical and logistical benefits of double ovarian stimulation (DuoStim) in egg donation</div></div><div><h3>Design</h3><div>Prospective and observational study</div></div><div><h3>Subjects</h3><div>Sixty healthy egg donors aged 18–35, all with regular menstrual cycles, normal karyotype, and adequate ovarian reserve</div></div><div><h3>Exposure</h3><div>Each donor underwent two consecutive ovarian stimulations and oocyte retrievals within a single menstrual cycle, applying a standardized protocol</div></div><div><h3>Main Outcome Measures</h3><div>The primary outcome was the number of oocytes retrieved per stimulation. Secondary outcomes included blastulation rate, clinical pregnancy rate, implantation rate, and clinical miscarriage rate.</div></div><div><h3>Results</h3><div>The mean number of oocytes retrieved was significantly higher in the first stimulation compared with the second one (19.8 ± 2.0 vs. 13.3 ± 2.2). Similarly, the number of metaphase II oocytes was greater in the first stimulation (16.4 ± 1.8 vs. 11.5 ± 2.1). Despite the reduced oocyte yield, oocyte survival rates after vitrification were comparable between stimulations (91.8% follicular vs. 90.5% luteal). Usable blastocyst rates were also similar (42.8% vs. 49.1%), and clinical outcomes did not differ significantly: implantation rates were 69.8% (follicular) and 66.1% (luteal), and clinical pregnancy rates were 71.2% and 66.7%, respectively. The miscarriage rate was slightly lower in the follicular phase (7.7% vs. 12.4%), but this difference was not statistically significant. No cases of ovarian hyperstimulation syndrome or other serious adverse events were observed.</div></div><div><h3>Conclusions</h3><div>DuoStim is a safe and efficient approach in egg donation, maximizing cycle efficiency and convenience by enabling two retrievals in a single cycle. Although the second stimulation yields fewer oocytes, oocyte and embryo quality remain unaffected. These findings support the use of DuoStim in donor programs, especially where time and resource optimization are priorities.</div></div>","PeriodicalId":34409,"journal":{"name":"FS Reports","volume":"7 1","pages":"Pages 12-16"},"PeriodicalIF":2.2,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146175364","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Frozen embryo transfer outcomes in patients with prior cesarean delivery: a focus on endometrial lining parameters","authors":"Emily A. Clarke M.D. ,&nbsp;Jing Wu Ph.D. ,&nbsp;Hannah Milad M.D. ,&nbsp;Kerry Flannagan Ph.D. ,&nbsp;Jiarui Wang MS ,&nbsp;Joseph Lee B.A. ,&nbsp;Luis Hoyos M.D. ,&nbsp;Meike Uhler M.D. ,&nbsp;Michael Homer M.D. ,&nbsp;Jenna Friedenthal M.D. ,&nbsp;Alan B. Copperman M.D. ,&nbsp;Phillip Romanski M.D ,&nbsp;Mary Morris M.D., Ph.D.","doi":"10.1016/j.xfre.2025.12.006","DOIUrl":"10.1016/j.xfre.2025.12.006","url":null,"abstract":"<div><h3>Objective</h3><div>To evaluate the association between prior mode of delivery (cesarean vs. vaginal) and endometrial thickness in the subsequent frozen embryo transfer (FET) cycle. The secondary aim was to evaluate FET cycle outcomes.</div></div><div><h3>Design</h3><div>Retrospective cohort study.</div></div><div><h3>Subjects</h3><div>This multicenter study included patients with one previous live birth who initiated a subsequent, autologous FET cycle from January 2012 to December 2024. Patients were grouped by mode of prior delivery: cesarean or vaginal.</div></div><div><h3>Exposure</h3><div>Cesarean or vaginal delivery.</div></div><div><h3>Main Outcome Measures</h3><div>The primary outcome was endometrial thickness at final lining assessment. Secondary outcomes included FET cycle cancellation rate due to thin or fluid-filled endometrium, pregnancy, and live birth rates. Subgroup analyses evaluated outcomes of euploid FET cycles only.</div></div><div><h3>Results</h3><div>A total of 11,131 FET cycles consisting of 5,149 from patients with prior cesarean and 5,982 from patients with prior vaginal delivery were included. Endometrial thickness in the subsequent FET cycle was similar between cohorts (cesarean: 10.4 mm [10.3–10.5 mm]; vaginal: 10.4 mm [10.3–10.4 mm]). The FET cycle cancellation rate due to thin endometrium was comparable (cesarean: 1.3%, vaginal: 1.2%; adjusted relative risk [aRR] 1.02 [0.72–1.43]); cancellation due to endometrial fluid accumulation was higher in the cesarean cohort (1.0% vs. 0.5%; aRR 2.22 [1.40–3.58]). Cesarean delivery was associated with lower live birth (49.5% vs. 53.0%; aRR 0.95 [0.90–0.98]) and clinical pregnancy (60.5% vs. 64.1%; aRR 0.95 [0.90–0.99]), with similar rates of clinical pregnancy loss (cesarean: 10.6%, vaginal: 10.6%; aRR 0.95 [0.84–1.07]). Similar trends were observed in patients undergoing euploid FET, with lower live birth demonstrated in those with a prior cesarean (55.3% vs. 60.3%; aRR 0.91 [0.84–0.98]), but similar chance of clinical pregnancy loss (cesarean: 9.1%, vaginal: 9.4%; aRR 0.95 [0.77–1.17]).</div></div><div><h3>Conclusion</h3><div>Although patients can be reassured that a prior cesarean does not appear to be associated with reduced endometrial thickness, receptivity in FET cycles may be diminished, as reflected by lower subsequent live birth rates. One possible explanation is an altered endometrial environment, given the increased risk of cycle cancellation due to endometrial fluid accumulation in patients with prior cesarean delivery.</div></div>","PeriodicalId":34409,"journal":{"name":"FS Reports","volume":"7 1","pages":"Pages 17-24"},"PeriodicalIF":2.2,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146175362","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of estetrol and drospirenone combination therapy on alleviation of the pelvic pain of endometriosis: a randomized control trial","authors":"Tasuku Harada M.D., Ph.D. ,&nbsp;Masayoshi Nogami M.Sc. ,&nbsp;Masato Iizuka M.Pharm. ,&nbsp;Kanna Meguro M.Agr. ,&nbsp;Chrispin Manda Ph.D. ,&nbsp;Masashi Hirayama M.Pharm. ,&nbsp;Takao Kobayashi M.D., Ph.D.","doi":"10.1016/j.xfre.2025.12.002","DOIUrl":"10.1016/j.xfre.2025.12.002","url":null,"abstract":"<div><h3>Objective</h3><div>To study the impact of estetrol (E4), a novel native estrogen with selective tissue activity, on endometriosis-associated pelvic pain (EAPP) and global impressions of endometriosis pain.</div></div><div><h3>Design</h3><div>Multicenter, randomized, open-label, active-controlled study; 88 eligible Japanese participants with endometriosis were randomized to either the E4 15 mg/drospirenone (DRSP) 3 mg group or the ethinyl estradiol (EE) 20 μg/DRSP 3 mg group. Participants received assigned treatment for 12 weeks.</div></div><div><h3>Subjects</h3><div>Japanese patients aged ≥20 and &lt;50 years diagnosed with endometriosis. Eligibility required an EAPP score ≥40 mm on the visual analogue scale (VAS).</div></div><div><h3>Intervention</h3><div>Participants were randomized 1:1 to E4/DRSP or EE/DRSP groups.</div></div><div><h3>Main Outcome Measures</h3><div>Change in EAPP intensity from baseline to week 12, assessed using a 100 mm VAS, and patient’s global impression of improvement (PGI-I) and clinician’s global impression of improvement (CGI-I) scores after 12 weeks.</div></div><div><h3>Results</h3><div>Changes in the most severe EAPP from baseline to week 12 were similar between the groups. The VAS score over time profiles showed lower scores with E4/DRSP than with EE/DRSP during the nonmenstrual period. Responders were defined as participants achieving ≥70 mm reduction from the most severe VAS score at baseline on ≥80% of nonmenstrual period days. On Fisher’s exact test comparing responders and nonresponders, significant differences in patient’s and clinician’s global impression of improvement scores were seen. Furthermore, E4/DRSP had significantly higher responder rates than EE/DRSP.</div></div><div><h3>Conclusion</h3><div>The E4/DRSP combination therapy has the potential to improve the quality of life of patients with endometriosis, with greater amelioration of nonmenstrual EAPP than EE/DRSP.</div></div><div><h3>Trial registration</h3><div>JPRN-jRCT2080225090</div></div>","PeriodicalId":34409,"journal":{"name":"FS Reports","volume":"7 1","pages":"Pages 38-45"},"PeriodicalIF":2.2,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146174790","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Quantification of per- and polyfluoroalkyl substances in plasma and follicular fluid of patients undergoing in vitro fertilization in Iowa: A pilot study","authors":"Prapti Singh-Herren D.O., M.S. ,&nbsp;Samantha Good M.S. ,&nbsp;Karen M. Summers M.P.H. C.H.E.S. ,&nbsp;Joseph A. Charbonnet Ph.D. ,&nbsp;Amy E. Sparks Ph.D. ,&nbsp;Aileen F. Keating Ph.D.","doi":"10.1016/j.xfre.2025.11.009","DOIUrl":"10.1016/j.xfre.2025.11.009","url":null,"abstract":"","PeriodicalId":34409,"journal":{"name":"FS Reports","volume":"7 1","pages":"Pages 90-93"},"PeriodicalIF":2.2,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146174792","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The problem with calling it “unexplained infertility”","authors":"Richard J. Paulson M.D., M.S.","doi":"10.1016/j.xfre.2025.12.007","DOIUrl":"10.1016/j.xfre.2025.12.007","url":null,"abstract":"","PeriodicalId":34409,"journal":{"name":"FS Reports","volume":"7 1","pages":"Pages 1-2"},"PeriodicalIF":2.2,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146174797","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A single biomarker may not yield a reliable binary clinical answer: B cell lymphoma 6 testing and resulting interventions for endometriosis in infertility care","authors":"Arti Taggar M.D., M.P.H. ,&nbsp;Amanda Ulrich M.D. ,&nbsp;Yuliana Tan Ph.D. ,&nbsp;Danielle E. Luciano M.D. ,&nbsp;Melinda Sanders M.D. ,&nbsp;Elise T. Courtois Ph.D. ,&nbsp;Claudio Benadiva M.D.","doi":"10.1016/j.xfre.2025.11.005","DOIUrl":"10.1016/j.xfre.2025.11.005","url":null,"abstract":"<div><h3>Objective</h3><div>To study the associations of B cell lymphoma 6 (BCL6) in endometrial endometriosis, and to determine a practice’s experience testing BCL6 in patients with recurrent pregnancy loss/recurrent implantation failure (RPL/RIF).</div></div><div><h3>Design</h3><div>Retrospective chart review.</div></div><div><h3>Subjects</h3><div>Endometrial samples were collected at the time of laparoscopy from 19 reproductive-aged individuals with known stage II–IV endometriosis. Endometrium biopsies were also collected from eight healthy controls, at a single academic center.</div></div><div><h3>Exposure</h3><div>Results using standard immunohistochemical staining for BCL6 on endometrial biopsies from October 2019 to March 2023 were obtained. For the in vitro fertilization patients with a positive BCL6 result (HSCORE<strong>≥</strong>1.4), postbiopsy interventions on the basis of the positive result were then compared with positive patients who did not receive treatment for their positive result of BCL6 test.</div></div><div><h3>Main Outcome Measures</h3><div>Outcomes for the embryo transfer cycle immediately after that biopsy/intervention were analyzed. Descriptive statistics with independent t-tests for continuous data, and χ² or Fischer’s exact tests for categorical data were used. A two-sided <em>P</em> value of &lt;.05 was considered statistically significant.</div></div><div><h3>Results</h3><div>We found no significant upregulation of <em>BCL6</em> or downstream target gene expression changes in endometriosis relative to the control group, indicating no significant single-cell differences in the BCL6 endometriosis pathway among endometrial samples from these patients with known endometriosis. A total of 33 RPL/RIF patients were treated on the basis of a positive result vs. those who were not treated. These two groups also did not have any statistically significant differences in their age, body mass index, history of live births, previous pregnancy losses, or HSCOREs. Of the patients treated for their positive <em>BCL6</em> results, 20 (86%) were treated with leuprolide acetate, 9 (39%) with an aromatase inhibitor, and 1 (4%) was surgically managed with a laparoscopy in preparation for their frozen embryo transfer. There were no differences in implantation rate, miscarriage rate, or ongoing pregnancy rate among the patients who were and were not treated for their positive <em>BCL6</em> result.</div></div><div><h3>Conclusion</h3><div>The relationship between BCL6 and endometriosis may not be the golden solution to a single marker focus for testing, or for subsequent therapy planning among infertility patients. Clinicians should be cautious in using single marker testing for diagnosing and treating endometriosis in patients without strong additional therapeutic evidence.</div></div>","PeriodicalId":34409,"journal":{"name":"FS Reports","volume":"7 1","pages":"Pages 31-37"},"PeriodicalIF":2.2,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146175368","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Black Fertility Matters Too: community-centered seminars improve fertility knowledge","authors":"Alexis B. Hood M.D. ,&nbsp;Bridget Huepfel B.A. ,&nbsp;Stacey L. Edwards-Dunn D.M.I.N., M.P.H. ,&nbsp;Tia Jackson-Bey M.D., M.P.H. ,&nbsp;Amanda J. Adeleye M.D.","doi":"10.1016/j.xfre.2025.12.004","DOIUrl":"10.1016/j.xfre.2025.12.004","url":null,"abstract":"<div><h3>Objective</h3><div>Studies have demonstrated that Black individuals have less fertility knowledge compared with White individuals. We aimed to determine if a community-centered fertility education seminar (the Black Fertility Matters Too tour) could improve basic fertility knowledge in the Black community.</div></div><div><h3>Design</h3><div>Pretest-posttest study.</div></div><div><h3>Subjects</h3><div>Individuals self-identifying as Black who attended a community-based half-day fertility seminar.</div></div><div><h3>Exposure</h3><div>Seminar lectures on fertility, infertility treatments, third-party reproduction, and access to care taught by healthcare providers of color, as well as personal stories from individuals with infertility.</div></div><div><h3>Main Outcome Measures</h3><div>Improvement in fertility knowledge (preseminar vs. postseminar) measured by the total score on the Cardiff Fertility Knowledge Scale (CFKS). Secondary outcomes included improvement in individual CFKS items and follow-up scores several weeks later.</div></div><div><h3>Results</h3><div>A total of 270 people attended the Black Fertility Matters Too seminars, and 102 participants completed preseminar and postseminar surveys. The mean age of participants was 40 ± 10.14 years. Most participants identified as women (90.2%) and Black (94.06%), with 44.55% currently experiencing infertility. The mean preseminar and postseminar CFKS scores were 66.0% (±17.5) and 77.5% (±15.79), respectively. Knowledge of the definition and prevalence of infertility increased significantly, as did knowledge of ovarian function, ovarian aging, and the influence of sexually transmitted infections on fertility. Twenty-four participants (23% of enrolled survey participants) completed a follow-up survey, on average, 5.85 months later, which demonstrated no significant difference from postseminar scores. All follow-up participants found the seminars helpful, and some individuals with infertility indicated they were motivated to seek fertility care after participating in the seminar.</div></div><div><h3>Conclusion</h3><div>Community-centered seminars on fertility can improve basic fertility knowledge and may motivate individuals to seek fertility care. Further studies should evaluate how best to standardize these interventions and address structural barriers to fertility care in Black communities.</div></div>","PeriodicalId":34409,"journal":{"name":"FS Reports","volume":"7 1","pages":"Pages 62-68"},"PeriodicalIF":2.2,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146175365","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comments on “Safety and pharmacology of AMY109, a long-acting anti–interleukin-8 antibody, for endometriosis: a double-blind, randomized phase 1 trial”","authors":"Shashank Dokania B.H.M.S,&nbsp;Parth Aphale Ph.D.,&nbsp;Himanshu Shekhar B.H.M.S.","doi":"10.1016/j.xfre.2025.09.007","DOIUrl":"10.1016/j.xfre.2025.09.007","url":null,"abstract":"","PeriodicalId":34409,"journal":{"name":"FS Reports","volume":"7 1","pages":"Page 94"},"PeriodicalIF":2.2,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146174791","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Possible drug reaction with eosinophilia and systemic symptoms after spironolactone therapy for clinical hyperandrogenism: a case report","authors":"Sandy Hoang M.D.,&nbsp;Danielle Strom M.D.,&nbsp;Kathleen M. Brennan M.D.","doi":"10.1016/j.xfre.2025.11.004","DOIUrl":"10.1016/j.xfre.2025.11.004","url":null,"abstract":"<div><h3>Objective</h3><div>To present a case of possible drug reaction with eosinophilia and systemic symptoms (DRESS) after spironolactone and to review existing literature on serious cutaneous adverse reactions to spironolactone.</div></div><div><h3>Design</h3><div>Case report and literature review</div></div><div><h3>Subject</h3><div>A 29-year-old woman with hyperandrogenism who developed a febrile, pruritic, generalized rash 1 week after initiating spironolactone.</div></div><div><h3>Exposure</h3><div>Discontinuation of spironolactone</div></div><div><h3>Main Outcome Measures</h3><div>Resolution of symptoms, RegiSCAR diagnostic assessment for DRESS</div></div><div><h3>Results</h3><div>Symptoms resolved after discontinuation and recurred upon two separate rechallenges. Although laboratory and histopathological data were not available to definitively confirm the diagnosis of DRESS, clinical features were suspicious for DRESS on the basis of RegiSCAR criteria. The patient met five diagnostic criteria, which would classify this as a “possible” case. Other reported cutaneous reactions to spironolactone include linear immunoglobulin A bullous dermatosis and erythema multiforme.</div></div><div><h3>Conclusion</h3><div>Clinicians should be aware of the rare but potentially serious risk of DRESS in patients treated with spironolactone. Prompt recognition, drug discontinuation, and supportive management are essential. Diagnostic confirmation with laboratory studies and skin biopsy should be pursued in suspected cases.</div></div>","PeriodicalId":34409,"journal":{"name":"FS Reports","volume":"7 1","pages":"Pages 81-85"},"PeriodicalIF":2.2,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146174794","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Novel sperm selection device on the basis of microfluidics improves usable blastocyst rates, embryo morphology, and morphokinetic patterns: sibling cohort prospective study","authors":"Fernando Meseguer M.Sc. ,&nbsp;Laura Carrión-Sisternas M.Sc. ,&nbsp;Ana del Arco M.Sc. ,&nbsp;Rocío Rivera-Egea Ph.D. ,&nbsp;Carmen Vidal Ph.D. ,&nbsp;José Alejandro Remohí Ph.D. ,&nbsp;Marcos Meseguer Ph.D.","doi":"10.1016/j.xfre.2025.09.008","DOIUrl":"10.1016/j.xfre.2025.09.008","url":null,"abstract":"<div><h3>Objective</h3><div>To assess the performance of a novel microfluidic sperm selection device, SwimCount Harvester (SCH), compared with the Swim-up (SU) method, analyzing both sperm quality and the laboratory’s key performance indicators.</div></div><div><h3>Design</h3><div>Prospective, double-blind study using sibling oocytes.</div></div><div><h3>Subjects</h3><div>This study included 100 patients undergoing intracytoplasmic sperm injection. Both partners had normal karyotypes. Male participants provided only fresh ejaculated semen samples without total asthenozoospermia, globozoospermia, azoospermia, or cryptozoospermia. Female partners had at least 2 mature oocytes retrieved.</div></div><div><h3>Exposure</h3><div>Semen samples were analyzed to assess concentration, total progressive motile count, vitality, morphology, chromatin structure integrity, and deoxyribonucleic acid fragmentation index (DFI) before and after sperm selection. Subsequently, each sample was divided into two aliquots and processed using either the SCH device or the Swim-up technique. Retrieved oocytes from each patient were divided into two groups and microinjected with sperm from the corresponding preparation method. The injected oocytes were cultured in time-lapse incubators to collect morphokinetic data and apply artificial intelligence (AI)–based tools for assessing oocytes and embryos.</div></div><div><h3>Main Outcome Measures</h3><div>Primary outcomes included fertilization rate, usable blastocyst rate, good-quality blastocyst rate, euploidy rate, embryo morphokinetics, and AI score to predict pregnancy for each embryo. Secondary outcomes encompassed oocyte quality (using AI tool) and sperm quality parameters.</div></div><div><h3>Results</h3><div>SwimCount Harvester yielded significantly higher sperm concentration, morphologically normal sperm, improved chromatin stability, and lower DFI. The usable blastocyst rates were higher in the SCH group (SCH, 40.5%, vs. SU, 34.5%), as well as the good-quality blastocyst rates (SCH, 30.8%, vs. SU, 23.4%). Time to blastocyst formation was shorter in the SCH group (SCH, 106.9 hours, vs. SU, 109.5 hours). Fertilization rates (SCH, 78.8%, vs. SU, 77.0%), euploidy rates (SCH, 40.4%, vs. SU, 37.2%), and AI scores to predict pregnancy (SCH, 5.7%, vs. SU, 4.6%) were comparable. Subgroup analyses revealed higher usable blastocyst and good-quality embryo rates in the SCH group among cases with a DFI of &gt;20%, as well as a higher good-quality embryo rate in low-quality oocytes (AI score of ≤6) in the SCH group.</div></div><div><h3>Conclusion</h3><div>SwimCount Harvester improved sperm quality compared with Swim-up. Furthermore, the SCH device increased the usable blastocyst rate and embryo quality rate and reduced time to blastocyst formation. Nevertheless, no significant differences were observed in the fertilization rates, euploidy rates, or AI scores.</div></div>","PeriodicalId":34409,"journal":{"name":"FS Reports","volume":"6 4","pages":"Pages 436-445"},"PeriodicalIF":2.2,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145711806","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}